ClinicaliQ Trial Snapshot
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting • Phase III • Oncology • NCT05774951.
- Treatment being tested: Camizestrant (a selective estrogen receptor degrader) versus standard endocrine therapy in ER+/HER2- early breast cancer patients who have completed at least 2 years of adjuvant endocrine therapy.
- Patient eligibility overview: Women with ER+/HER2- early breast cancer at intermediate or high risk of recurrence who have finished definitive locoregional therapy and completed minimum 2 years of standard adjuvant endocrine treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Eligibility Snapshot
- : * Women and Men, ≥18 years at the time of screening (or per national guidelines) * Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol. * Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy * Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor) * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 * Adequate organ and marrow function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.